Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Biogen CEO Chris Viehbacher targets subcutaneous Leqembi release for Alzheimers treatment Biogens Chris Viehbacher outlines ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...